Although previous studies have confirmed that the combination of ICIs with BRAF plus MEK inhibitors dramatically improves health outcomes in patients with BRAFV600 mutation-positive melanoma, it is still unknown whether considerable drug prices and intolerant AEs could be balanced by enhanced health benefits. This evidence concerns the gene MAP2K7 and melanoma.